| Literature DB >> 27757173 |
Anne Rochtus1, Raf Winand2, Griet Laenen2, Elise Vangeel3, Benedetta Izzi4, Christine Wittevrongel4, Yves Moreau2, Carla Verpoorten5, Katrien Jansen5, Chris Van Geet1, Kathleen Freson4.
Abstract
BACKGROUND: Neural tube defects (NTDs) are severe congenital malformations that arise from failure of neurulation during early embryonic development. The molecular basis underlying most human NTDs still remains largely unknown. Based on the hypothesis that folic acid prevents NTDs by stimulating methylation reactions, DNA methylation changes could play a role in NTDs. We performed a methylome analysis for patients with myelomeningocele (MMC). Using a candidate CpG analysis for HOX genes, a significant association between HOXB7 hypomethylation and MMC was found.Entities:
Keywords: BMP4; DNA methylation; Epigenetics; Myelomeningocele; Neural tube defects; SOX18; Spina bifida
Mesh:
Substances:
Year: 2016 PMID: 27757173 PMCID: PMC5064967 DOI: 10.1186/s13148-016-0272-8
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 6.551
Top six differentially methylated genes investigated by HM450k and selected for validation with Sequenom EpiTYPER
| Gene | Illumina ID | Chr | Mapinfo | WateRmelon | IMA R-package | Gene group | ||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||
| ABAT Chr16p13 | cg01881182 | 16 | 8806531 | 0.0017 | −0.20 | 0.0047 | −0.15 | 5′ UTR |
| cg16586594 | 16 | 8806569 | 0.0005 | −0.18 | 0.0005 | −0.19 | 5′ UTR | |
| cg08834902 | 16 | 8806690 | 0.0047 | −0.23 | 0.0047 | −0.16 | 5′ UTR | |
| SLC1A6 Chr19p13 | cg12695707 | 19 | 15121333 | 0.0002 | −0.27 | 0.0005 | −0.16 | TSS1500 |
| cg09470638 | 19 | 15121509 | 0.0010 | −0.25 | 0.0048 | −0.14 | TSS200 | |
| cg02489552 | 19 | 15121531 | 0.0002 | −0.14 | 0.0002 | −0.21 | TSS200 | |
| SOX18 Chr20q13 | cg02231404 | 20 | 62679635 | 0.0010 | −0.20 | 0.0010 | −0.21 | Body |
| cg22138735 | 20 | 62679713 | 0.0005 | −0.17 | 0.0005 | −0.17 | Body | |
| TEPP Chr16q21 | cg04370442 | 16 | 58019866 | 0.0047 | −0.15 | 0.0075 | −0.16 | Body |
| cg12499872 | 16 | 58019893 | 0.0005 | −0.31 | 0.0005 | −0.15 | Body | |
| CNTNAP1 Chr17q21 | cg16308533 | 17 | 40838983 | 0.0005 | −0.17 | 0.0010 | −0.19 | Body |
| cg11629889 | 17 | 40839022 | 0.0002 | −0.14 | 0.0010 | −0.16 | Body | |
| SNED1 Chr2q37 | cg23491743 | 2 | 241989271 | 0.0017 | −0.16 | 0.0030 | −0.17 | Body |
| cg25241559 | 2 | 241989379 | 0.0005 | −0.15 | 0.0005 | −0.17 | Body | |
Selection is performed after analysis with two pipelines and application of three selection criteria: (i) absolute β value difference >0.10; (ii) P value <0.05; and (iii) presence of multiple CpGs per locus. Nucleotide positions accord to NCBI build 37/hg19. Gene group is defined relative to the nearest open reading frame: within 1500 (TSS1500) or 200 bp (TSS200) of a transcription start site, in the 5′ untranslated region (5′ UTR), the first exon of a transcript (exon), in the body of gene (body) or the 3′ UTR (3′ UTR). These six genes were selected for the validation study using Sequenom EpiTYPER
β diff β difference, Chr chromosome, Illumina ID identification according to HM450k, MMC myelomeningocele
Fig. 1Gene ontology enrichment map based on top differentially methylated genes in MMC patients. The map displays three clusters of functionally related gene-sets in MMC patients versus controls (a–c). Gray nodes represent GO classes and the size of each node is correlated with its significance (adjusted P value). Green and red nodes represent hypomethylated and hypermethylated genes, respectively. The intensity of the color is correlated with β difference
Fig. 2Validation of the top six differentially methylated genes by Sequenom EpiTYPER in MMC patients versus controls. Left: methylation pattern for each CpG unit within the amplicons. Multiple t test was performed for each CpG. *P value <0.05. Right: boxplot representing methylation pattern with box = 25th and 75th percentiles; bars = min and max values. The mean methylation level of each group is shown above the plot. The validation study is performed for 83 MMC patients and 30 controls. *CpGs were first identified by HM450k
Fig. 3Demethylation studies and gene expression analysis. Demethylation studies were performed using 5 μM 5-aza-2′-deoxycytidine in HEK cell line. a Sanger sequencing showing demethylation of SOX18 after 5-aza-2′-deoxycytidine treatment. The CpGs from the SOX18 amplicon are annotated below the sequence. b Gene expression analysis of top six genes using qRT-PCR. Standard standard culture conditions, AZA 5-aza-2′-deoxycytidine. *P value <0.05, ***P value <0.001
Fig. 4Phenotype analysis of gene overexpression in zebrafish embryos. Pax2a staining after microinjection of abat mRNA (a) and sox18 mRNA (b). Wild-type (WT) zebrafish show expression in the hindbrain, hindbrain-midbrain boundary, neural tube, mesoderm, optic stalk, otic vesicle, and pronephric duct. Spinal cord malformation is indicated with an arrow. c Phenotype analysis after pax2a staining at 24 hpf resulted in respectively 50 and 74 % embryos with an affected phenotype after abat and sox18 overexpression. Folic acid supplementation after gene overexpression did not significantly influence the phenotype. ***P value <0.001
Fig. 5SOX18 methylation for the family study and the BMP4 study by Sequenom EpiTYPER. a Mean methylation and standard deviation of SOX18 methylation for the family study and the BMP4 study. The mean methylation level of each group is shown above the plot. *P value <0.05, **P value <0.01, ***P value <0.001, ****P value <0.0001. b Methylation pattern for each CpG unit within the SOX18 amplicon for the family study. Multiple t test was performed for each CpG. *P value <0.05. c Methylation pattern for each CpG unit within the SOX18 amplicon for the BMP4 study. Multiple t test was performed for each CpG. *P value <0.05. The family study consists of MMC patients, their unaffected siblings, and their parents (n = 5 for each group). The BMP4 study describes the family of a patient with a BMP4 deletion. The father is carrier of the BMP4 deletion